Cryobiopsy for lung cancer lymph nodes
Transbronchial EBUS-guided TBNA and Cryobiopsy of Mediastinal Lymph Nodes in Patients Nonsuspicious for Lung Cancer, Using Different Cryoprobe Freezing Times
This study is testing a new way to take tissue samples from lymph nodes in lung cancer patients using freezing techniques to see if it gives better results than the usual methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 136 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Basel) |
| Trial ID | NCT06921681 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of ultrasound-guided cryobiopsy for obtaining tissue samples from mediastinal and hilar lymph nodes in patients with lung cancer. It aims to determine the optimal freezing times and number of biopsies needed to maximize diagnostic yield compared to traditional methods. Participants will undergo cryobiopsy procedures with varying freezing durations to assess the quality of tissue samples for histological analysis. The study seeks to improve diagnostic accuracy and inform targeted therapies for lung malignancies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 90 with mediastinal or hilar lesions requiring diagnostic bronchoscopy.
Not a fit: Patients with contraindications to bronchoscopy or those with certain blood disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the accuracy of lung cancer diagnoses and improve treatment options for patients.
How similar studies have performed: Previous studies have indicated that cryobiopsy can yield better diagnostic results than traditional methods, suggesting a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least one mediastinal lesion or hilar 1 cm or longer in the short axis requiring diagnostic bronchoscopy * Age between 18 and 90 years * Written informed consent after participant's information Exclusion Criteria: * Age \< 18 and \> 90 years * Lacking ability to form an informed consent (including impaired judgement, communication barriers) * Contraindication against bronchoscopy (e.g. co-morbidities) * Mediastinal abscess or cyst * Extraordinary blood supply of the lesion visualized by EBUS bronchoscope * INR \> 1.5 or Thrombocytes \< 100 G/l * Clopidogrel or other new antiplatelet drugs within 7 days before biopsy (salicylic acid alone allowed) * Anticoagulation with NOAC within 48 hours before biopsy * Pulmonary lesions suspicious of lung carcinoma
Where this trial is running
Basel
- Jürgen Hetzel — Basel, Switzerland (Recruiting)
Study contacts
- Study coordinator: Carolin Steinack
- Email: carolin.steinack@usz.ch
- Phone: 0041 44 255 8689
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.